Replies to post #545 on Bristol Myers Squibb (BMY)

[chmcnfunds]

It sure seems that PFE is the most frequently mentioned purchaser and as a a holder would be just fine with 30%. It was overbought back when it was $75/76.

Current consensus is only ~10%

Consensus Ratings for Bristol-Myers Squibb Company (NYSE:BMY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 10 Hold Ratings, 10 Buy Ratings
Consensus Rating: Hold (Score: 2.43)
Consensus Price Target: $62.35 (10.81% upside)

https://www.marketbeat.com/stocks/NYSE/BMY/

Recall the Barrons article this past weekend:

"Bristol-Myers Could Return 40% in Two to Three Years" by Vito J. Racanelli points out that Bristol-Myers Squibb Co (NYSE: BMY) may not be a high-flying tech stock, but it is a leader in high-tech cancer treatments. Though the drugmaker has taken a beating after a disappointing lung-cancer trial and a related setback involving its Opdivo, see how patient investors could be rewarded"

BMY